Serum indicators in functional high-risk multiple myeloma patients undertaking proteasome inhibitors therapy: a retrospective study

References

• Palumbo A, Bringhen S, Ludwig H, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood. 2011 Oct 27;118(17):4519–4529.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011 Mar 17;364(11):1046–1060.
   PubMed Web of Science ®Google Scholar
• Cavo M, Rajkumar SV, Palumbo A, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011;117(23):6063–6073. doi:10.1182/blood-2011-02-297325
   PubMed Web of Science ®Google Scholar
• Facon T, Dimopoulos MA, Meuleman N, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 2020;34(1):224–233. doi:10.1038/s41375-019-0539-0
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): multiple myeloma. Version 4.2023. 2023.
   Google Scholar
• Greil C, Engelhardt M, Finke J, et al. Allogeneic stem cell transplantation in multiple myeloma. Cancers (Basel). 2021 Dec;14(1):55.
   Web of Science ®Google Scholar
• Ri M, Iida S, Maruyama D, et al. HLA genotyping in Japanese patients with multiple myeloma receiving bortezomib: an exploratory biomarker study of JCOG1105 (JCOG1105A1). Cancer Sci. 2021;112(12):5011–5019. doi:10.1111/cas.15158
   PubMed Web of Science ®Google Scholar
• Obeng EA, Carlson LM, Gutman DM, et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006;107(12):4907–4916. doi:10.1182/blood-2005-08-3531
   PubMed Web of Science ®Google Scholar
• Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142–152. doi:10.1056/NEJMoa1411321
   PubMed Web of Science ®Google Scholar
• Mateos MV, San Miguel JF. Management of multiple myeloma in the newly diagnosed patient. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):498–507.
   PubMedGoogle Scholar
• Durie BG, Jacobson J, Barlogie B, et al. Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials. J Clin Oncol. 2004;22(10):1857–1863. doi:10.1200/JCO.2004.05.111
   PubMed Web of Science ®Google Scholar
• Spencer A, Mollee P, Blacklock HA, et al. Real-world outcome for newly diagnosed patients with functional high-risk myeloma - a myeloma and related diseases registry analysis. Blood. 2019;134(Supplement_1):269–269. doi:10.1182/blood-2019-129431
   Google Scholar
• Soekojo CY, Chung TH, Furqan MS, et al. Genomic characterization of functional high-risk multiple myeloma patients. Blood Cancer J. 2022;12(1):24. doi:10.1038/s41408-021-00576-3
   PubMed Web of Science ®Google Scholar
• Vincent Rajkumar S. Multiple myeloma: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol. 2014 Oct;89(10):999–1009. doi:10.1002/ajh.23810
   PubMed Web of Science ®Google Scholar
• Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol. 2000 Sep;65(3):175–181.
   PubMed Web of Science ®Google Scholar
• Augustson BM, Begum G, Dunn JA, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002–Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005;23(36):9219–9226. doi:10.1200/JCO.2005.03.2086
   PubMed Web of Science ®Google Scholar
• Charlinski G, Tyczynska A, Malecki B, et al. Risk factors and causes of early mortality in patients with newly diagnosed multiple myeloma in a “real-world” study: experiences of the Polish Myeloma Group. Pol Arch Intern Med. 2021 Jun 29;131(6):527–534.
   PubMedGoogle Scholar
• Dimopoulos MA, Roussou M, Gkotzamanidou M, et al. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia. 2013;27(2):423–429. doi:10.1038/leu.2012.182
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Delimpasi S, Katodritou E, et al. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol. 2014;25(1):195–200. doi:10.1093/annonc/mdt483
   PubMed Web of Science ®Google Scholar
• Chanan-Khan AA, San Miguel JF, Jagannath S, et al. Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment. Clin Cancer Res. 2012;18(8):2145–2163. doi:10.1158/1078-0432.CCR-11-0498
   PubMed Web of Science ®Google Scholar
• Ludwig H, Drach J, Graf H, et al. Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica. 2007;92(10):1411–1414. doi:10.3324/haematol.11463
   PubMed Web of Science ®Google Scholar
• Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266–2275. doi:10.1038/s41375-019-0435-7
   PubMed Web of Science ®Google Scholar
• Murphy PT, Baldeo C, O'Kelly P, et al. Dialysis-dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma. Br J Haematol. 2014;165(6):890–891. doi:10.1111/bjh.12818
   PubMed Web of Science ®Google Scholar
• Haynes RJ, Read S, Collins GP, et al. Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre. Nephrol Dial Transplant. 2010;25(2):419–426. doi:10.1093/ndt/gfp488
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–e548. doi:10.1016/S1470-2045(14)70442-5
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Updated diagnostic criteria and staging system for multiple myeloma. Am Soc Clin Oncol Educ Book. 2016;35:e418–e423.
   PubMedGoogle Scholar
• Wuilleme S, Robillard N, Lode L, et al. Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. Leukemia. 2005;19(2):275–278. doi:10.1038/sj.leu.2403586
   PubMed Web of Science ®Google Scholar
• Callander NS, Baljevic M, Adekola K, et al. Nccn guidelines(R) insights: multiple myeloma, version 3.2022. J Natl Compr Canc Netw. 2022;20(1):8–19. doi:10.6004/jnccn.2021.7112
   PubMed Web of Science ®Google Scholar
• Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467–1473. doi:10.1038/sj.leu.2404284
   PubMed Web of Science ®Google Scholar
• Binder M, Nandakumar B, Rajkumar SV, et al. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia. 2022 Mar;36(3):801–808.
   Google Scholar
• Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122–1128. doi:10.1038/leu.2013.313
   PubMed Web of Science ®Google Scholar
• Burger AM, Seth AK. The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. Eur J Cancer. 2004;40(15):2217–2229. doi:10.1016/j.ejca.2004.07.006
   PubMed Web of Science ®Google Scholar
• Wang YT, Chu B, Zhou TG, et al. Clinical and genomic characterization of Chinese patients with functional high-risk multiple myeloma: a real-world validation study. Front Oncol. 2023;13:1110693. doi:10.3389/fonc.2023.1110693
   PubMed Web of Science ®Google Scholar
• Bobin A, Gruchet C, Guidez S, et al. Novel non-immunologic agents for relapsed and refractory multiple myeloma: a review article. Cancers. 2021 Oct;13(20):5210.
   PubMed Web of Science ®Google Scholar
• Besse A, Besse L, Kraus M, et al. Proteasome inhibition in multiple myeloma: head-to-head comparison of currently available proteasome inhibitors. Cell Chem Biol. 2019;26(3):340–351e3. doi:10.1016/j.chembiol.2018.11.007
   PubMed Web of Science ®Google Scholar
• Haertle L, Buenache N, Cuesta Hernandez HN, et al. Genetic alterations in members of the proteasome 26S subunit, AAA-ATPase (PSMC) gene family in the light of proteasome inhibitor resistance in multiple myeloma. Cancers (Basel). 2023 Jan;15(2):532.
   PubMed Web of Science ®Google Scholar
• Barrio S, Stuhmer T, Da-Via M, et al. Spectrum and functional validation of PSMB5 mutations in multiple myeloma. Leukemia. 2019;33(2):447–456. doi:10.1038/s41375-018-0216-8
   PubMed Web of Science ®Google Scholar
• Tsvetkov P, Sokol E, Jin D, et al. Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers. Proc Natl Acad Sci U S A. 2017;114(2):382–387. doi:10.1073/pnas.1619067114
   PubMed Web of Science ®Google Scholar
• Haertle L, Barrio S, Munawar U, et al. Single-nucleotide variants and epimutations induce proteasome inhibitor resistance in multiple myeloma. Clin Cancer Res. 2023;29(1):279–288. doi:10.1158/1078-0432.CCR-22-1161
   PubMed Web of Science ®Google Scholar
• Clark AD, Shetty A, Soutar R. Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Rev. 1999;13(2):79–90. doi:10.1016/S0268-960X(99)90014-0
   PubMed Web of Science ®Google Scholar
• Kiba T, Ito T, Nakashima T, et al. Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival. BMC Cancer. 2014;14:462. doi:10.1186/1471-2407-14-462
   PubMed Web of Science ®Google Scholar
• Park WJ, Kim SY, Kim YR, et al. Bortezomib alleviates drug-induced liver injury by regulating CYP2E1 gene transcription. Int J Mol Med. 2016;37(3):613–622. doi:10.3892/ijmm.2016.2461
   PubMed Web of Science ®Google Scholar
• Saeki I, Terai S, Fujisawa K, et al. Bortezomib induces tumor-specific cell death and growth inhibition in hepatocellular carcinoma and improves liver fibrosis. J Gastroenterol. 2013;48(6):738–750. doi:10.1007/s00535-012-0675-z
   PubMed Web of Science ®Google Scholar
• Kim Y, Kim KY, Lee SH, et al. A case of drug-induced hepatitis due to Bortezomib in multiple myeloma. Immune Netw. 2012;12(3):126–128. doi:10.4110/in.2012.12.3.126
   PubMedGoogle Scholar
• Cornelis T, Beckers EA, Driessen AL, et al. Bortezomib-associated fatal liver failure in a haemodialysis patient with multiple myeloma. Clin Toxicol. 2012;50(5):444–445. doi:10.3109/15563650.2012.673624
   Web of Science ®Google Scholar
• Jain A, Malhotra P, Suri V, et al. Cholestasis in a patient of multiple myeloma: a rare occurrence of bortezomib induced liver injury. Indian J Hematol Blood Transfus. 2016 Jun;32(Suppl 1):181–183.
   PubMedGoogle Scholar